Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients

1. Comp PC, Jacocks RM, Rubenstein C, Radcliffe R. A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity. J Lab Clin Med. 1981; 97: 637-45.Search in Google Scholar

2. Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol. 1984; 37: 772-7.10.1136/jcp.37.7.772Search in Google Scholar

3. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood. 1987; 69: 1315-9.10.1182/blood.V69.5.1315.1315Search in Google Scholar

4. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology. 1991; 101: 1382-90.10.1016/0016-5085(91)90092-YSearch in Google Scholar

5. Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, et al. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res. 2008; 121: 763-8.10.1016/j.thromres.2007.08.011Search in Google Scholar

6. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost. 2001; 85: 667-70.10.1055/s-0037-1615651Search in Google Scholar

7. Reverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost. 2006; 4: 717-20.10.1111/j.1538-7836.2006.01887.xOpen DOISearch in Google Scholar

8. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No J Thromb Haemost. 2006; 4: 721-3.10.1111/j.1538-7836.2006.01886.xSearch in Google Scholar

9. Violi F, Alessandri C, Ferro D, Saliola M, Cordova C, Musca A, et al. Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis. J Clin Pathol. 1989; 42: 1246-9.10.1136/jcp.42.12.1246Open DOISearch in Google Scholar

10. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology. 1992; 15: 672-6.10.1002/hep.1840150420Search in Google Scholar

11. Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. Association between high values of Ddimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. CALC Group. Thromb Haemost. 1996; 76: 177-83.10.1055/s-0038-1650549Search in Google Scholar

12. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol. 2001; 96: 1581-6.10.1111/j.1572-0241.2001.03781.xSearch in Google Scholar

13. Copley AL, Niewiarowski S, Marechal J. A micromethod of euglobulin fibrinolysis in plasma of human subjects and small laboratory animals. J Lab Clin Med. 1959; 53:468-73.Search in Google Scholar

14. Toschi V, Rocchini GM, Motta A, Fiorini GF, Cimminiello C, Violi F, et al. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. Biomed Pharmacother. 1993; 47: 345-52.10.1016/0753-3322(93)90084-XOpen DOISearch in Google Scholar

15. Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol. 2000; 95: 3218-24.10.1111/j.1572-0241.2000.03299.x11095345Search in Google Scholar

16. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol. 2007; 46: 727-33.10.1016/j.jhep.2007.01.01517316874Open DOISearch in Google Scholar

17. Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res. 2008; 121: 675-80.10.1016/j.thromres.2007.07.00817870147Search in Google Scholar

18. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology. 1993; 17: 78-83.10.1002/hep.1840170115Open DOISearch in Google Scholar

19. Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R. Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology. 1993; 18: 1350-6.10.1002/hep.1840180611Search in Google Scholar

20. Booth NA. The natural inhibitors of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Singapore: Churchill Livingstone, 1994. p. 625-37Search in Google Scholar

21. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44: 217-31.10.1016/j.jhep.2005.10.01316298014Search in Google Scholar

22. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell’Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006; 44: 440-5.10.1002/hep.2126616871542Open DOISearch in Google Scholar

23. Aytac S, Turkay C, Bavbek N, Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis. 2007; 18: 623-6.10.1097/MBC.0b013e328285d80e17890949Open DOISearch in Google Scholar